Tercica is committed to supporting the pediatric endocrinologists who prescribe our products, and to ensuring a healthier future for every child who is on Increlex^® (mecasermin [rDNA origin] injection) therapy. We also recognize that the most valuable data on product safety and efficacy must come directly from the front lines of patient care. With this in mind, we encourage pediatric endocrinologists to become clinical investigators in the Increlex^® Growth Forum Database (IGFD).

This open-label, multi-center, observational study is designed to obtain long-term safety and efficacy data for Increlex^®. By gathering and analyzing real-world information on how patients are responding to Increlex^® therapy, we are able to provide the clinical community with a better understanding of how Increlex can help their patients. Eligibility criteria include patients who are just beginning therapy, or those who have been previously treated with Increlex^®.

All healthcare professionals who participate in the IGFD Registry receive one-on-one, on-site training in using our simple, Web-based data collection system. Data is collected through a secure Web site, and kept confidential in full compliance with federal regulations. Among the types of data included for analysis are demographics, previous medical histories, physical growth parameters and dosing history. As data is collected on patients enrolled at centers throughout the United States, it is then analyzed for use in scientific publications, presentations and at annual meetings of clinical investigators and study coordinators.

To inquire about participating in the IGFD Registry call 1.866.TERCICA.